Regulation of vascular tone is critical to the maintenance of vascular perfusion pressure and blood flow. Within the vessel wall, endothelial cells (ECs), vascular smooth muscle cells (VSMCs), and elements of the cellular matrix (fibroblasts) interact with each other through the local production of autocrine, paracrine, and intracrine factors. Vascular cells both sense and adapt to hemodynamic factors to signal appropriate changes in growth and contractility and determine the adaptive response of the vessel to chronic elevations in arterial pressure. Vascular wall restructuring is a dynamic process that is characterized by hypertrophy and hyperplasia of VSMCs as well as loss of arterial elasticity due to disruption of the balance between the production and degradation of extracellular matrix proteins. 1, 2 The regulation of vascular growth is thus a key element influencing arterial compliance, distensibility, and resistive changes that occur when luminal pressure is elevated or the vascular wall intima is disrupted.
VSMC growth is stimulated by factors produced by neighboring ECs; released from circulating platelets, neutrophils, and monocytes; and secreted by fibroblasts and VSMCs in an autocrine fashion. Factors that promote vascular growth include platelet-derived growth factor (PDGF), basic fibroblast growth factor, angiotensin II (Ang II), and endothelin. [1] [2] [3] [4] The mitogenic actions of Ang II may play an important role in vascular proliferation, because inhibition of its formation or activity attenuates neointimal formation after balloon injury of rat arteries. 5, 6 Daemen et al 7 showed that Ang II infusions into rats markedly stimulated DNA synthesis in both neointimal and medial smooth muscle cells. Su et al 8 recently reported that the Ang II-induced proliferative effects were independent of the Ang II-induced pressor response.
In contrast, atrial natriuretic factor (ANF), prostacyclin, prostaglandin (PG) E 2 , PGE 1 , PGD 2 , and nitric oxide (NO) inhibit the growth of cultured VSMCs. 9 -15 ANF inhibited the growth of cultured VSMCs through stimulation of guanylate cyclase and the production of cGMP. 9, 10 Overexpression of prostacyclin synthase in rat VSMCs increased prostacyclin production and decreased DNA synthesis in response to stimulation by serum. 16 Pharmacological agents that increase the intracellular concentration of cAMP or cGMP (membrane-permeant cyclic nucleotide analogues, forskolin, or phosphodiesterase inhibitors) reduced serum-stimulated growth of rabbit and rat VSMCs. 17, 18 Collectively, these results suggest that ANF, NO, and prostaglandins inhibit VSMC growth through an increase in the cellular content of cyclic nucleotides.
The number of factors that may modulate or antagonize the proliferative effects of Ang II was enriched by the discovery that the N-terminal heptapeptide angiotensin-(1-7) [Ang-(1-7)] acts as an antitrophic agent. 19, 20 These observations are important, because they indicate that the renin-angiotensin system has evolved a mechanism to intrinsically control the agonistic actions of Ang II on both short-and long-term regulation of arterial pressure and vascular growth. Because Ang II stimulates the release of arachidonic acid-derived autacoids and modulates the activity of NO and bradykinin, Ang-(1-7) may be a link to explain the multilevel interaction between proliferative and antiproliferative signal transduction systems. This review describes our continuing investigation of the role of Ang-(1-7) in the regulation of arterial pressure and vascular wall function.
Ang-(1-7) Is a Novel Hormone of the Renin-Angiotensin System
Past experiments demonstrated that Ang-(1-7) opposes the actions of Ang II (as recently reviewed 21 ). Ang-(1-7), which circulates in blood at concentrations similar to those of Ang II, 22, 23 rises after inhibition of either angiotensin-converting enzyme (ACE) or long-term administration of AT 1 receptor blockers. [23] [24] [25] [26] [27] Ang-(1-7) is derived from Ang I and Ang II by tissue peptidases, including neprilysin, thimet oligopeptidase, and prolyl endopeptidase. 28 -31 The elevation in plasma Ang-(1-7) in response to ACE inhibitor treatment is suppressed by blocking the activity of neprilysin with ecadotril, demonstrating that neprilysin is responsible for the generation of circulating Ang-(1-7). 32 Ang-(1-7) is also a substrate for ACE, 33 suggesting that ACE inhibition increases Ang-(1-7) not only by blocking Ang II formation but also by preventing Ang-(1-7) degradation. In keeping with this interpretation, the administration of a selective Ang-(1-7) monoclonal antibody or inhibition of Ang-(1-7) formation reverses the antihypertensive effect produced by 9-day administration of lisinopril and losartan in spontaneously hypertensive rats (SHR). 34, 35 The combination therapy or lisinopril alone also causes a large increase in the circulating half-life of Ang-(1-7), 36 further demonstrating that ACE is directly involved in the degradation of the heptapeptide.
Antitrophic Actions of Ang-(1-7)
Because Ang-(1-7) releases prostaglandins-both PGI 2 and PGE 2 -from VSMCs, 37, 38 19 The reduction in serum-stimulated thymidine incorporation by Ang-(1-7) was dose-dependent, with a peak effect at a dose of 1 mol/L (Figure 1 ). Higher concentrations of Ang-(1-7) had no further effect. At the 10-nmol/L dose of Ang-(1-7), thymidine incorporation was inhibited by 25%, whereas the EC 50 for inhibition of serum-stimulated VSMC growth was 115 nmol/L. Maximal inhibition by 1 mol/L Ang-(1-7) was Ϸ40% of the response to 1% FBS, which is similar to the growth inhibition previously reported for ANF. 10 Total cell number in response to treatment with Ang-(1-7) was also determined with a Coulter counter. The number of cells per well increased to 142% of basal after treatment with 1% serum, as shown in Figure 1 . Treatment of serum-stimulated cells with 1 mol/L Ang-(1-7) significantly reduced the number of cells per well (to 109% of basal). By comparison, Ang II caused a dose-dependent increase in [ 3 H]thymidine incorporation, with a maximal increase of 314% above basal with 1 mol/L Ang II, and increased the number of cells per well to 145% of basal values. 19 It is possible that the EC 50 for Ang-(1-7) determined in these experiments is much higher than the actual concentration required to induce antimitogenic effects. This interpretation is based on the finding that 125 I-Ang-(1-7) incubated with cultured cells was rapidly degraded to free tyrosine, Val-Tyr, or Ang-(3-7) with only 15% of the initial 125 I-Ang-(1-7) remaining intact after a 90-minute incubation. 39 These data are consistent with the in vivo findings of a half-life of 9 seconds for Ang-(1-7), which is 1 ⁄6 that of Ang II in the circulation. 40 Abell et al 9 reported a similar rapid degradation of the growth-inhibitory peptide ANF in VSMCs. These data suggest that the antitrophic effects of Ang-(1-7) in VSMCs may be underestimated by its rapid metabolism in intact cells. The antitrophic effects of Ang-(1-7) may, in fact, be due to metabolic fragments of the heptapeptide.
Reduction of Neointimal Formation by Ang-(1-7) After Vascular Injury
Ang II infusion into rats markedly stimulated DNA synthesis in both neointimal and medial smooth muscle cells in a normal carotid artery. 7, 8 Treatment of rats with ACE inhibitors to prevent Ang II formation or AT 1 receptor antagonists to block Ang II cellular effects inhibited neointimal formation and medial remodeling after vascular injury. 5, 6 Thus, Ang II increases vascular growth in vivo, in agreement with its stimulation of thymidine uptake and cell number in cultured VSMCs. Because Ang II and Ang-(1-7) have opposite effects on VSMC growth, we determined the effect of Ang-(1-7) on medial and neointimal proliferation stimulated by balloon catheter injury to the rat carotid artery. Intravenous infusion of Ang-(1-7) with a chronically implanted minipump (24 g ⅐ kg Ϫ1 ⅐ h Ϫ1 at a rate of 5 L/h for 12 days) increased the plasma Ang-(1-7) concentration to 166Ϯ41.2 fmol/mL (nϭ6) from 46.9Ϯ11 fmol/mL (nϭ8) in carotid artery-injured rats infused with saline. Plasma concentrations of Ang II (27.3Ϯ7.6 compared with 27Ϯ11.0 fmol/mL), diastolic and systolic pressures, and heart rate were similar in rats infused with Ang- (1-7) or saline, 20 in agreement with our previous studies. 41 Histological examination of carotid artery cross sections showed that balloon-catheter injury resulted in the formation of a neointima in both the saline-and Ang-(1-7)-infused rats, as shown in Figure 2 . Morphometric analysis indicated that Ang-(1-7) infusion had no effect on the medial area of the injured or the contralateral uninjured artery compared with saline controls (Figure 3 ). In contrast, Ang-(1-7) infusion significantly reduced the neointimal area compared with rats infused with saline (0.10Ϯ0.009 versus 0.063Ϯ0.011 mm 2 , nϭ6 to 8, PϽ0.05). Thus, exogenous Ang-(1-7) infusion reduced neointimal formation after vascular injury. Most importantly, the effects of Ang-(1-7) on the vasculature occurred in the absence of changes in blood pressure and at concentrations of the peptide only 2-fold higher than in saline-treated rats.
In previous studies, we showed that infusions of Ang-(1-7) at the same concentration increased urinary prostaglandin excretion. 41 Thus, one potential mechanism for our observations in the injured carotid artery is that Ang-(1-7) stimulated prostaglandin production to inhibit vascular proliferation. Ang-(1-7) increased prostaglandin formation in rat, 38 porcine, 37 and rabbit 42 VSMCs. Consistent with this, infusion of prostacyclin analogues was antiproliferative after vascular injury. 43 Because prostacyclin receptors on VSMCs activated adenylate cyclase to produce cAMP 44 and compounds that increased the intracellular concentration of cAMP reduced mitogen-activated protein kinase activity in VSMCs and fibroblasts, 45 Ang-(1-7) may inhibit growth by stimulating prostacyclin production, increasing cellular cAMP, and reducing mitogen-activated protein kinase activity. Furthermore, the vasodilation of pial arteries by Ang-(1-7) and the depressor component of the response to Ang-(1-7) in the pithed rat were reduced by prior treatment with the cyclooxygenase inhibitor indomethacin, indicating that these hemodynamic responses to Ang-(1-7) were also mediated by prostaglandins. 46, 47 Thus, an increase in prostacyclin production in response to Ang-(1-7) may mediate both the antihypertensive and antitrophic effect of the peptide.
Our results suggest that the signal transduction mechanism for the antiproliferative effects of Ang-(1-7) entail liberation of prostacyclin through an AT (1) (2) (3) (4) (5) (6) (7) receptor-mediated event.
Muthalif et al 42 reported that Ang-(1-7) activated a cytosolic phospholipase A 2 (cPLA 2 ) in rabbit VSMCs to release arachidonic acid. We showed that the Ang-(1-7)-mediated release of prostaglandins occurs via a pathway that involves no changes in cellular inositol phosphate concentrations or mobilization of intracellular calcium. 37, 48, 49 Thus, Ang-(1-7) may also activate a calcium-independent PLA 2 to release arachidonic acid for prostacyclin production. Alternatively, the heptapeptide may be operating on a receptor subtype that is either linked to activation of a potassium channel 50 or may stimulate the secondary release of kinin. In this context, studies by us 51 and others 31 showed that Ang-(1-7) augments the vasodepressor actions of bradykinin. This action may be related in part to the observation that Ang-(1-7) functions as an endogenous inhibitor of the C-terminal domain of somatic ACE. We confirmed this finding, first demonstrated by use of isolated somatic ACE, 33 in intact normal and hypertensive rats. 36 It is evident that further studies are necessary to dissect the signal transduction pathway that is activated by Ang-(1-7). Studies in this direction may uncover important intracellular sites regulating the interplay between second messenger molecules and kinases in the regulation of trophic functions.
What Receptor Is Activated by Ang-(1-7)?
Although the majority of vascular responses to Ang II are mediated by the AT 1 receptor, 3, 4 several studies suggest that stimulation of the AT 2 receptor attenuates vascular growth through the release of cGMP. [52] [53] [54] However, the antiproliferative effects of Ang-(1-7) cannot be explained by the activation of an AT 2 receptor by Ang- (1-7) . Attenuation of thymidine incorporation by Ang-(1-7) in the presence of 1% FBS was unaffected by antagonists selective for AT 1 (L158,809) or AT 2 (PD123177) receptors ( Figure 4A, left) . It is unlikely that the inability of PD123177 to block the antiproliferative effects of Ang-(1-7) is the result of incomplete AT 2 receptor blockade, because the antagonist was used at a concentration of 10 mol/L, a concentration sufficient to block AT 2 -mediated events. In contrast, a 10-mol/L concentration of the sarcosine derivative of Ang II ([Sar 1 -Thr 8 ]-Ang II, Sarthran) completely blocked growth inhibition by Ang-(1-7), which indicates that the effect of the heptapeptide was a result of the activation of an angiotensin receptor pharmacologically distinct from either AT 1 3 H]thymidine incorporation was attenuated by the AT 1 -selective antagonists losartan and L158,809, whereas the AT 2 antagonist PD123177 was ineffective ( Figure 4B) , confirming that the AT 1 receptor mediates the mitogenic response to Ang II. However, addition of Ang II to VSMCs in the presence of the AT 1 antagonist losartan or L158,809 caused a significant reduction in the incorporation of [ 3 H]thymidine compared with the unstimulated control (to 71.0% and 60.5% of basal, respectively). Micromolar concentrations of the AT 2 antagonist PD123319 blocked Ang II-mediated inhibition of the proliferation of ECs, 52 VSMCs transfected with the AT 2 receptor, 53 and VSMCs from embryonic or neonatal rats. 54 These findings suggest that the Ang II-mediated inhibition of VSMC growth that we observed in VSMCs from adult rats might also be mediated by an AT 2 receptor. However, if Ang II inhibited [ 3 H]thymidine incorporation in VSMCs from adult rats through activation of an AT 2 receptor, then thymidine incorporation would be increased when AT 2 receptors were blocked, as observed in endothelial cells 52 and VSMCs transfected with the AT 2 receptor. 53 We did not observe an increase in [ 3 H]thymidine incorporation in the presence of Ang II and 10 mol/L PD123177 or CGP42112A ( Figure  3B ). Furthermore, high concentrations of CGP42112A have agonistic properties at some AT 2 receptors; 10 mol/L CGP42112A reduced thymidine incorporation and potentiated the antimitogenic properties of Ang II in rat coronary ECs. 52 We did not observe an agonistic effect of CGP42112A in adult rat VSMCs or a potentiation of the response to Ang II, suggesting that Ang II did not inhibit vascular growth through activation of an AT 2 receptor in adult VSMCs. Thus, we hypothesize that Ang II inhibited growth of VSMCs from adult rats through activation of a non-AT 1 , non-AT 2 receptor when AT 1 receptors are blocked. Because Ang II competed for 125 I-Ang-(1-7) binding to BAECs, albeit with a lower affinity than Ang-(1-7), 56 Ang II may inhibit growth of losartan-treated VSMCs through activation of the non-AT 1 , non-AT 2 receptor that is activated by Ang-(1-7). Consistent with this interpretation is the possibility that Ang II may be rapidly converted into Ang-(1-7) in experiments using cultured cells. We previously showed the presence of Ang-(1-7)-forming enzymes in ECs and VSMCs. 29, 30 The time of exposure needed to measure a change in the incorporation of thymidine (Ͼ30 minutes) is more than sufficient for Ang II to be converted into Ang-(1-7). Further work is clearly required to understand the pharmacological mechanism and receptor subtype at which Ang II is acting when binding to the AT 1 receptor is prevented. Furthermore, the potential interactions between the AT 2 and AT (1) (2) (3) (4) (5) (6) (7) receptors will require a precise definition of alternative receptor mechanisms and a more thorough evaluation of the effects of PD123319 on angiotensin receptors.
Recognition of the physiological responses to Ang-(1-7) occurred concurrently with the identification of subtypeselective ligands for different molecular forms of Ang II receptors. Characterization of physiological or cellular responses to Ang-(1-7) was thus accompanied by attempts to define the receptor subtype mediating these responses. Al- though some of the characterized responses to Ang-(1-7) were blocked by AT 1 or AT 2 receptor antagonists, 47, 48, [57] [58] [59] Ang-(1-7) is a poor competitor at the prototypical AT 1 receptor in VSMCs 37, 38 or the AT 2 receptor in differentiated NG108-15 or pancreatic cells. 60, 61 The majority of responses to Ang-(1-7) were not blocked by an AT 1 or AT 2 receptor antagonist. 37, 47, 51, 62, 63 These include release of prostaglandins from C6 glioma cells and porcine endothelial cells, 37, 62 relaxation of canine coronary artery rings, 51, 63 and the reduction in blood pressure in the pithed rat. 47 21 consistent with functional effects of Ang-(1-7) in canine and porcine coronary arteries. 51, 63 In more recent studies of vessels from rats treated with the combination of lisinopril and losartan for 9 days as described above, 34, 35 we found evidence of non-AT 1 , non-AT 2 binding in the endothelial layer of the aorta as well as within the smooth muscle and adventitial layers ( -7) binding site within the vasculature. We propose that this non-AT 1 , non-AT 2 receptor mediates the antihypertensive and antitrophic effects of Ang-(1-7). We refer to this receptor as the AT (1) (2) (3) (4) (5) (6) (7) receptor, in accordance with the guidelines established by the International Union of Pharmacology Nomenclature Subcommittee for Angiotensin Receptors. 64, 65 The AT (1) (2) (3) (4) (5) (6) (7) receptor is defined by its sensitivity to Ang-( 
Concluding Remarks
Vascular growth is regulated by a balance between proliferative and antiproliferative factors. Two members of the family of angiotensin peptides-Ang II and Ang-(1-7)-oppose each other in regulating vascular growth. Ang II is clearly mitogenic in cultured VSMCs as well as in intact arteries in the absence of hemodynamic changes. In contrast, Ang-(1-7) inhibits stimulated growth of VSMCs and reduced neointimal formation at concentrations of the peptide only 2-fold higher than in saline-treated rats and in the absence of changes in blood pressure. A balance between the tissue concentrations of Ang II and Ang-(1-7) is thus critical in the long-term maintenance of vessel structure. AT (1) (2) (3) (4) (5) (6) (7) receptor Ang-(1-7) Ͼ Ang II 0 0 100 100
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ARBs indicates Ang II receptor blockers.
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